Our writers are rare disease experts
Preparing for a rare disease or orphan drug launch? Let Med Communications customize a launch team for you. Our scientific writers, 90% of whom hold PharmD degrees, are highly educated and experienced in creating content for rare diseases and orphan drugs. Our team leads serve as resident product experts, and their deep level of knowledge about your product and company helps ensure content produced by the team is accurate and effective. Team leads working in shared models serve a low number of clients to ensure optimal product knowledge.
Our clients have relied on our team for product launches relating to a range of rare diseases and orphan drugs. Below is a list of some of the topics our writers have experience with.
Rare Disease and Orphan Drugs
- Acromegaly
- Alpha-1 antitrypsin deficiency
- Atypical hemolytic uremic syndrome (aHUS)
- Beta thalassemia
- Bleeding disorders including congenital fibrinogen deficiency, congenital FXIII deficiency, acquired coagulation factor deficiency (ACFD) induced by vitamin K antagonists (VKAs), and von Willebrand disease (VWD)
- Castleman disease
- Chronic granulomatous disease
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Chronic immune thrombocytopenic purpura (ITP)
- Cardiomyopathies
- Cardiometabolic lipid disorders
- Cryopyrin-associated periodic syndromes (CAPS)
- Cushing’s disease/syndrome
- Cystic fibrosis
- Familial chylomicronemia syndrome (FCS)
- Generalized lipodystrophy
- Generalized myasthenia gravis (gMG)
- Hemophilia A and B
- Hereditary angioedema (HAE)
- Hypophosphatasia (HPP)
- Idiopathic hypersomnia (IH)
- Idiopathic pulmonary fibrosis
- Invasive fungal infections (IFIs) [invasive aspergillosis (IA), invasive mucormycosis (IM)]
- Lysosomal storage disorders
- Medullary thyroid cancer
- Neurofibromatosis type 1
- Neuromyelitis optica spectrum disorder
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Polycythemia
- Primary humoral immunodeficiency (PI)
- Veno-occlusive disease (VOD)
- VEXAS syndrome
Oncology
- Acute myeloid leukemia (AML)
- Advanced basal cell carcinoma (BCC)
- Breast cancer
- Chronic lymphocytic leukemia (CLL)
- Gastric cancer
- Gastrointestinal cancer
- Genitourinary cancer
- Gynecological cancer
- Head and neck cancers
- Hodgkin lymphoma (HL)
- Immuno-oncology
- Lung cancer
- Melanoma
- Metastatic castration-resistant prostate cancer
- Mantle cell lymphoma (MCL)
- Multiple myeloma (MM)
- Myelofibrosis/polycythemia vera/essential thrombocytopenia
- Non-muscle invasive bladder cancer (NMIBC)
- Ovarian cancer
- Prostate cancer (PC)
- Renal cell carcinoma
- T Cell lymphomas (ALCL, mycosis fungoides, PTCL)
- Urothelial/bladder cancer
- Waldenstrom’s macroglobulinaemia (WM)
Contact us today to learn how our team can support your next rare disease launch: 877-477-0977 or https://medcommunications.com/contact-us/.
